Vireo Growth (VREOF) Cash from Operations Growth (3y) (2023 - 2026)
Vireo Growth (VREOF) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.19 Bn | 87.33 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 32.52 Bn | 30.58 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.22 Bn | 21.07 Bn | 648.10 Mn | 7.32% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.29 Bn | 18.48 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.72 Bn | 16.40 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.59 Bn | 12.16 Bn | 785.00 Mn | 27.85% |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn | 72.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72.53% |
| Dec 31, 2025 | 71.55% |
| Sep 30, 2025 | -47.74% |
| Jun 30, 2025 | -15.46% |
| Mar 31, 2025 | 20.48% |
| Dec 31, 2024 | 6.16% |
| Sep 30, 2024 | 20.87% |
| Jun 30, 2024 | 90.86% |
| Mar 31, 2024 | 37.92% |
| Dec 31, 2023 | -109.91% |
| Sep 30, 2023 | 35.21% |
| Jun 30, 2023 | 32.83% |
| Mar 31, 2023 | -11.55% |